Section Review: Central & Peripheral Nervous Systems: 5-HT₃ receptor antagonists as antiemetic agents in cancer chemotherapy

References

• HICKOK JT, MORROW GR: A biobehavioral model of patient-reported nausea: implications for clinical prac-tice. Adv. Med. Psychother. (1993) 6:227–240.
   Google Scholar
• MORROW GR: The assessment of nausea and vomiting:post problems, current issues, and suggestions for future research. Cancer (1984) 53:2267–2278.
   PubMed Web of Science ®Google Scholar
• GYLYS JA, DORAN KM, BUYNISKI JP: Antagonism ofcisplatin induced emesis in the dog. Res. Commun. Chem. Pathol. Pharmacol. (1979) 23:61–68.
   PubMedGoogle Scholar
• GRALLA RJ, HRI LM, PISKO SE et al.: Antlemetic efficacy of high dose metoclopramide: Randomized trials withplacebo and prochlorperazine in patients with chemo-therapy-induced nausea and vomiting. New Engl . J. Med. (1981) 305:905-909. First report of high-dose metoclopramide in antiemetic therapy.
   Google Scholar
• MCRITCHIE LE, MCCLELLAND CM, COOPER SM et al.: Dopamine antagonists as anti-emetics and as stimulants of gastric motility. In: Mechanisms of Gastrointestinal Motility and Secretion. Bennet A, Velo G (Eds.), Plenum Press, New York (YEAR):287–301.
   Google Scholar
• FORD APDW, BAXTER GS, EGLEN RM et al.: 5-hy-droxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT4 receptors. Eur.J. Pharmacol. (1992) 211:117–120,
   PubMed Web of Science ®Google Scholar
• FLORCZYK AP, SCHURIG JE, BRADNER WT: Cisplatin-in-duced emesis in the ferret a new animal modleL Cancer Treat. Rep. (1982) 66: 187–189.
   Google Scholar
• MINER WD, SANGER GJ: inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptorantagonism. Br. J. Pharmacol. (1986) 88:497-499. One of the early reports of 5-HT3 receptor antagonism in prevention of cisplatin-induced vomiting.
   Google Scholar
• BERGA P, BON J, LLENAS J etal.: Relacion entre los efectos antiemeticos de metocippramida (MTC) y clebopride (CLB) y el antagonism° de los receptores de 5-HT. Rev. Farmacol. Clin. Exp. (1986) 3:139.
   Google Scholar
• COSTALL B, DOMENEY AM, NAYLOR RJ et al.: 5-hy-droxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacol. (1986) 25:959.
   PubMed Web of Science ®Google Scholar
• DE MULDER PHM, SEYNAEVE C, VERMORKEN JB et al.: Ondansetron compared with high-dose metoclo-pramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Annals Int. Med. (1990) 113:834-840. Ondansetron was found to be superior to high-dose metoclo-pramide.
   Google Scholar
• CHEVALLIER B: Efficacy and safety of granisetron com- pared with high-dose metoclopramide plus dexametha-sone in patients receiving high-dose cisplatin in a single-blind study. Eur. J. Cancer (1990) 26\(Suppl. 1):S33–S36.
   Google Scholar
• BERMUDEZ J, BOYLE EA, MINER WD et al.: The anti-emetic potential of the 5-hydroxytryptamine3 receptor antago-nist BRL 43694. Br. J. Cancer (1988) 58:644–650,
   PubMed Web of Science ®Google Scholar
• CASSIDY J, RAINA V, LEWIS C et al.: Pharmacoltinetics and anti-emetic efficacy of BRL 43694, a new selective 5-HT3 antagonist. Br. J. Cancer (1988) 58:651–653.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, TURNER A, HAWTHORN J et al.: Ondan- setron with and without dexamethasone to treat che-motherapy-induced emesis. Lancet (1989) 2:1323. A report of a combination therapy with a 5-HT3 receptor antagonist (ondansetron) and dexamethasone.
   Google Scholar
• SMITH DB, NEWLANDS ES, SPRUYT OW et al.: Ondan- setron (GR 38032F) plus dexamethasone: effective anti- emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br.]. Cancer (1990) 61:323–324.
   PubMed Web of Science ®Google Scholar
• PETERS JA, LAMBERT JJ: Ekctrophysiology of 5-HT3 re-ceptors in neuronal cell lines. Trends Pharmacol. Sci. (1989) 10:172–175.
   PubMed Web of Science ®Google Scholar
• DERKACH V, SURPRENANT A, NORTH RA: 5-HT3 receptors are membrane ion channels. Nature (1989) 339:706-709.Characterisation of the 5-HT3 receptors.
   Google Scholar
• LATTIMER N, RHODES KF, SAVILLE VL: Possible differ-ences in the 5-HT3-like receptors in the rat and the guinea pig. Br.]. Pharmacol. (1989) 96:270P.
   Google Scholar
• BUTLER A, ELSWOOD CJ, BURRIDGE J et al.: The pharma-cological characterisation of 5-HT3 receptors in three Isolated preparations derived from guinea pig tissues. Br.]. Pharmacol. (1990) 101:591–598.
   PubMed Web of Science ®Google Scholar
• MARK AL: The Bezold-Jarisch reflex revisited: clinicalimplications of inhibitory reflexes originating in the heart.]. Am. Coll. Cardiol. (1983) 1:90–102.
   PubMed Web of Science ®Google Scholar
• CRAMER W, VAN DRIMMELEN M, LONG S et al.: Bufotenin:actions of 5-HT3 receptors. Fur. J. Pharmacol. (1990) 183:2148–2149.
   Google Scholar
• NEWBERRY NR, CHESHIRE SH, GILBERT MJ: Evidence thatthe 5-HT3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different. Br. J. Phar-macol. (1991) 102:615–620.
   PubMed Web of Science ®Google Scholar
• SEPULVEDA MI, LUMMIS SCR, MARTIN IL: 2-Methy1-5-HTis a partial agonist at 5-HT3 receptors in NIE-115 neuroblastoma cells. Br. J. Pharmacol. (1991) 102:138P.
   Google Scholar
• VAN WIJNGAARDEN I, TULP MTH, SONDIJN W: The con-cept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. (1990) 188:301–312.
   PubMed Web of Science ®Google Scholar
• FUKUDA T, SETOGUCHI M, INABA K et al.: The antiemeticprofile of Y-25130, a new selective 5-HT3 receptor an-tagonist. Eur. J. Pharmacol. (1991) 196:299–305.
   PubMed Web of Science ®Google Scholar
• SMALDONE L, ALBERTS D, AAPRO M et al.: Randomizeddouble-blind crossover comparison of batanopride (BMY 25801) and metoclopramide in patients receiving cisplatin-based chemotherapy. Ann. Oncol. (1990) 1(Suppl.):V(79, 2: 109.
   Google Scholar
• CLARKE DE, CRAIG DA, FOZARD JR: The 5-1IT4 receptor: naughtybut nice. Trends Pharmacol. Sci. (1989) 10:385–386.
   PubMed Web of Science ®Google Scholar
• ANDREWS PLR, DAVIDSON HIM: Activation of vagal af- ferent terminals by 5-hydroxytryptamine is mediated by the 5-HT3 receptor in the anaesthetised ferret.], Physiol. (1990) 422:92P. Sites of 5-HT3 receptor antagonism.
   Google Scholar
• WALLIS DI: Interaction of 5-hydroxytryptamine withautonomic and sensory neurones. In: The Peripheral Actions of 5-Hydroxytryptamine. Fozard JR (Ed.), Oxford Press, Oxford (1989):220–246.
   Google Scholar
• LESLIE RA, REYNOLDS DJM, ANDREWS PLR et al.: Evidencefor presynaptic 5-HT3 recognition sites on vagal affer-ent terminals in the brainstem of the ferret. Neuroscience (1990) 38:667–673.
   PubMed Web of Science ®Google Scholar
• REYNOLDS DJM, BARBER NA, GRAHAME-SMITH DG et al.:Cisplatin-evoked induction of c-fos protein in brain-stem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res. (1991) 565:231–236.
   PubMed Web of Science ®Google Scholar
• CARL PL, CUBEDDU LX, LINDLEY C et al.: Do humoralfactors mediate cancer chemotherapy-induced emesis? Drug Metab. Rev. (1989) 21:319–333.
   Google Scholar
• KING FD, SANGER GJ: 5-HT3 receptor antagonists. DrugsFuture (1989) 14:875–889.
   Google Scholar
• REISER G, HAMPRECHT B: Substance P and serotoninsynergistically activate a cation permeability in a neuro-nal cell line. Naunyn-Schmiedeberg's Arch. Pharmacol. (1988) 337(Suppl.):R109.
   Google Scholar
• CUBEDDU LX, HOFFMAN IS, FUENMAYOR NT et al.: Effi- cacy of ondansetron (GR 38032F) and the role of sero-tonin in cisplatin-induced nausea and vomiting. New Engl. J. Med. (1990) 322:810-816. Early report of ondansetron in prevention of acute nausea and vomiting.
   Google Scholar
• MARTY M, POUILLART P, SCHOLL S et al.: Comparison ofthe 5-hydroxytryptamine3 (serotonin) antagonist on-dansetron (GR 38032F) with high-dose metoclo-pramide in the control of cisplatin-induced emesis. New Engl.]. Med. (1991) 322:816–821.
   Web of Science ®Google Scholar
• WILKINSON JR, BROWN GW: The use of ondansetron inrepeated cycles of chemotherapy: an overview. Sympo-sium from Fur. Soc. Med. Oncol. Copenhagen (1990).
   Google Scholar
• WERNER K, FINN AL, GANDARA DR: Maintenance of antiemetic effectiveness with multiple courses of GR38032F and cisplatin abstract. Proc. Am. Soc. Clin. Oncol. (1989) 8:A1271.
   Google Scholar
• CUPISSOL DR, SERROU B, CAUBEL M: The efficacy of granisetron as a prophylactic anti-emetic and interven-tion agent in high-dose cisplatin-induced emesis. Eur.J. Cancer Clin. Oncol. (1990) 26\(Suppl. 1):S23-27. The original evaluation of granisetron in a placebo-controlled trial.
   Google Scholar
• SOUKOP M ON BEHALF OF THE GRANISETRON STUDYGROUP: A comparison of two dose levels of granisetron In patients receiving high-dose cisplatin. Eur. J. Cancer Clin. Oncol. (1990) 26\(Suppl. 1):515–19.
   Google Scholar
• SMITH IE: ON BEHALF OF THE GRANISETRON STUDY GROUP: A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Fur. J. Cancer Clin. Oncol. (1990) 26(Suppl.):S19–23.
   Google Scholar
• ROLLA F, TONATO M, BASURTO C et al.: Protection fromnausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with dexarnethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. (1989) 7:1693–1700.
   PubMed Web of Science ®Google Scholar
• BLIJHAM GH: ON BEHALF OF THE GRANISETRON STUDYGROUP: Does granisetron remain effective over multi-ple cycles? Fur. J. Cancer Clin. Oncol. (1992) 28A\(Suppl. 1):S17–21.
   Google Scholar
• LE1NBUNDGUT U, LANCRANJAN J: First results with ICS 205–930 (5-11T receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet (1987) 1:1198. First report of tropisetron in prevention of emesis.
   Google Scholar
• STAMATAKIS L, MICHEL J, VAN BELLE et al.: ICS 205–930: a dose finding study in the prevention of cisplatin-in-duced nausea and vomiting. Proc. Am. Soc. Clin. Oncol. (1989) 8:327. A dose finding study of tropisetron. GO
   Google Scholar
• VAN BELLE SJP, STAMATAKIS L, BLEIBERG H et al.: Dose- finding study in cisplatin-induced nausea and vomiting. Ann. Oncol. (1994) 5:821–825.
   PubMed Web of Science ®Google Scholar
• BLEIBERG H, VAN BELLE S, PARIDAENS R et al.: Compas-sionate use of a 5- HT3 receptor antagonist, tropisetron, In patients refractory to standard antiemetic treatment Drugs (1992) 43\(Suppl. 3):27–32.
   Google Scholar
• DOGLIOTTI L, ANTONACCI RA, PAZE E et al.: Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. Drugs (1992) 43 (Suppl. 3):6–10.
   Google Scholar
• SORBE B, ANDERSSON H, SCHMIDT M et al.: Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting - The Nordic experience. Support. Care Cancer (1994) 2(6):393–399. A large clinical study of tropisetron in various types of chemotherapy.
   Google Scholar
• SORBE B, HOGBERG T, GLIMELIUS B et al.: A randomized, multicenter study comparing the efficacy and tolerabil-ity of tropisetron, a new 5-HT3receptor antagonist, with a metoclopramkle-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer (1994) 73(2):445–454. A randomised study comparing tropisetron with a high-dose meto-clopramide cocktail.
   Google Scholar
• BREGNI M, SIENA S, DI NICOLA M et al.: Tropisetron plus haloperidol to ameliorate nausea and vomiting associ-ated with high-dose alkylating agent cancer chemother-apy. Eur. J. Cancer Clin. Oncol. (1991) 27:561–565.
   Google Scholar
• SORBE B, HOGBERG T, HIMMELMANN A et al.: Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur. J. Cancer (1994) 30:629-634. The first study evaluating tropisetron in combination with dex-amethasone.
   Google Scholar
• EINHORN LH, NAGY C, WERNER K et al.: Ondansetron: anew antiemetic for patients receiving cisplatin chemo-therapy. J. Clin. Oncol. (1990) 8:731–735.
   PubMed Web of Science ®Google Scholar
• BURTON G, HUANG A, LAZARUS H et al.: A double-blindrandomised comparison of three doses of iv ondan-setron for the prevention of emesis induced by multi-day cisplatin therapy [Abstract]. Proc. Am. Soc. Clin. Oncol. (1990) 9:1269.
   Google Scholar
• HAINSWORTH JD, OMURA GA, KHOJASTEH A et al.: GR38032F: anew antiemetic effective in a multiple day regimen of cisplatin (DDP) chemotherapy [Abstract]. Proc. Am. Soc. Clin. Oncol. (1989) 8:328.
   Google Scholar
• DIEHL V ON BEHALF OF THE GRANISETRON STUDY GROUP: Fractionated chemotherapy - granisetron or conventional antiemetics? Eur. J. Cancer Clin. Oncol. (1992) 28A (Suppl. 1):21–28. Granisetron in fractionated multiple-day chemotherapy.
   Google Scholar
• GERSHANOVICH M, KOLYGIN B, PIRGACH N: Tro-pisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann. Oncol. (1993) 4 (Suppl. 3):35–37.
   Google Scholar
• ROILA F, TONATO M, BASURTO C et al.: Protection fromnausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. (1989) 7:1693–1700.
   PubMed Web of Science ®Google Scholar
• MARTIN MM, DIAZ-RUBIO E, CASADO A etal.: Progressiveloss of antiemetic efficacy during subsequent courses of chemotherapy. Eur. J. Cancer Clin. Oncol. (1992) 28:430–432.
   Google Scholar
• WILKINSON JR, BROWN GW: The use of ondansetron inrepeated cycles of chemotherapy: an overview. Proceed-ings from Eur. Soc. Med. Oncol. Copenhagen, Denmark (1990).
   Google Scholar
• SOUKOP M, MCQUADE B, HUNTER E et al.: Ondansetron compared with metoclopratnide in the control of emesis and quality of life during repeated chemother- apy for breast cancer. Oncology (1992) 49: 295–304. Efficacy of ondansetron during repeated courses of chemotherapy.
   Google Scholar
• SMYTH J: Delayed emesis after high-dose cisplatin - the residual problem. Proceedings from Eur. Soc. Med. Oncol. Lyon, France (November 8, 1992).
   Google Scholar
• SORBE B: Tropisetron in the prevention of chemother-apy-induced nausea and vomiting: the Nordic experi-ence. Ann. Oncol. (1993) 4 (Suppl. 3):39–42.
   Google Scholar
• KRIS MG, GRALLA RJ, TYSON LB etal.: Controlling delayed vomiting: double-blind, randomized trial comparingplacebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. (1989) 7:108-114. An early and important study of delayed emesis.
   Google Scholar
• GANDARA DR: Progress in the control of acute and delayed emesis induced by cisplatin. Eur. J. Cancer (1991) 27:9–11.
   PubMed Web of Science ®Google Scholar
• NAVARI RM, MADAJEWICZ S, ANDERSON N et al.: Oral ondansetron for the control of cisplatin-induced de-layed emesis: a large, multicenter, double-blind, ran-domized comparative trial of ondansetron versus placebo. J. Clin. Oncol. (1995) 13:2408-2416. Ondansetron in prevention of delayed nausea and vomiting - a large American multicentre study.
   Google Scholar
• JOHNSTON D, LATREILLE J, LABERGE F et al.: Preventing nausea and vomiting during days 2–7 following highdose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CFG). Proceedings Am. Soc. Clin. Oncol. (1995) 14:529, Abstract #1745. Granisetron and dexamethasone in prevention of delayed emesis - a large Canadian multicentre study.
   Google Scholar
• JONES AL, HILL AS, SOUKOP M et al.: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately etnetogenic chemother-apy. Lancet (1991) 338:483-487. The first study comparing ondansetron and dexamethasone in delayed emesis.
   Google Scholar
• BECK TM: The pattern of emesis following high-dose cyclophosphamide and anti-emetic efficacy of ondan-setron. Anti-Cancer Drugs (1995) 6:237–242.
   PubMed Web of Science ®Google Scholar
• ROILA F, BALLATORI E, DE ANGELIS V et al.: Dexametha- sone, granisetron, or both for the prevention of nauseaand vomiting during chemotherapy for cancer. New Engl. J. Med. (1995) 332:1-5. An important study of combination therapy with granisetron and dexamethasone.
   Google Scholar
• ANDREWS PLR, BHANDARI P, DAVEY PT et al.: Are all 5-HT3 receptor antagonists the same? Eur.J. Cancer Clin. Oncol. (1992) 28A (Suppl. 1):S2-6. Pharmacological and phannacokinetic profiles of the 5-HT3 receptor antagonists.
   Google Scholar
• NAVARI R, GANDARA D, HESKETH P et al.: Comparative **clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. j Gun. Oncot (1995) 13(5): 1242–1248. A large randomised comparative trial of granisetron and ondan-setron.
   Google Scholar
• RUFF P, PASKA W, GOEDHALS L et al.: Ondansetron compared with granisetron in the prophylaxis of cis-platin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology (1994) 51:113–118.
   PubMed Web of Science ®Google Scholar
• NOBLE A, BREMER K, GOEDHALS L et al.: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: as-sessment of efficacy, safety and patient preference. Eur. J. Cancer (1994) 30A(8):1083–1088.
   PubMed Web of Science ®Google Scholar
• MARTY M, KLEISBAUER JP, FOURNEL P et al.: Is Navoban (tropisetron) as effective as Zofran (ondansetron) incisplatin-induced emesis? Anti-Cancer Drugs (1995) 6\(Suppl. 1):15–21, A large randomised comparative trial of ondansetron and tropisetron.
   Google Scholar
• STEWART A, MCQUADE B, CRONJE JDE et al.: Ondan-setron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, random-ized, parallel-group study. Oncology (1995) 52:202–210.
   PubMed Web of Science ®Google Scholar
• BONNETERRE J, HECQUET B ON BEHALF OF THE FRENCH NORTHERN ONCOLOGY GROUP: Granisetron (iv) com-pared with ondansetron (iv plus oral) in the prevention of nausea and vomiting induced by moderately-emeto-genic chemotherapy. A cross- over study. Eur. J. Cancer Oncol. (1996). In press.
   Google Scholar
• MASSIDDA B, LACONI S, FODDI MR et al.: Prevention of non-cisplatin-induced emesis: role of the antagonists of 5-HT3 receptors. Proc. Soc. Eur. Med. Oncol. (1994) 17:204.
   Google Scholar
• Marion Merrill Dow annual report 1994.
   Google Scholar
• JONES B: 5-HT3 receptor antagonists in anxiety and schizophrenia. Drug News Perspect. (1990) 3:106–111.
   Google Scholar
• BOEIJINGA PH, GALVAN M, BARON BM et al.: Charac-terisation of the novel 5-HT3 antagonists MDL 73147EP (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glionta cells. Eur. J. Pharmacol. (1992) 219:9–13.
   PubMed Web of Science ®Google Scholar
• BIGAUD M, ELANDS J, KASTNER PR et al.: Pharmacologyof the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dot Res. (1995) 34:289–296.
   Web of Science ®Google Scholar
• KIRCHNER V, AAPRO M, ALBERTO et al.: Early clinical trial of MDL 73147EF: a new 5-HT3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. Oncol. (1993) 4(6):481–484.
   PubMed Web of Science ®Google Scholar
• KRIS MG, GRUNBERG SM, GRALLA RJ et al.: Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J. din. Oncol. (1994) 12(5):1045–1049. Dose-ranging study of dolasetron.
   Google Scholar
• Itasetron. Drugs Future (1994) 19(11):1053–1054.
   Google Scholar
• TURCONI M, DONE= A, SCHIAVONE A et al.: Pharma- cological properties of a novel class of 5-HT3 receptor antagonists. Eur. J. Pharmacol. (1991) 203:203-211. Itasetron and a new class of 5-1-1T3 receptor antagonists.
   Google Scholar
• ROBERTSON DW, LACEFIELD WB, BLOOMQUIST W et al.: Zatosetron, a potent, selective, and long-acting 5-1IT3 receptor antagonist: Synthesis and structure-activity relationships. J. Med. Chem. (1992) 35:310–319.
   PubMed Web of Science ®Google Scholar
• COHEN ML, BLOOMQUIST W, GIDDA JS et al.: LY277359 maleate: a potent and selective 5-HT3 receptor antago-nist without gastroprokinetic activity. J. Pharmacol. Exp. Ther. (1990) 254:350–355.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MJ, CERIMELE BJ: Effect of zatisetron (LY-277359), a serotonergic receptor 5-HT3 antagonist on ipecac-induced emesis hi healthy men. Clin. Pharmacol. Ther. (1991) 49:171.
   Web of Science ®Google Scholar
• KAWAKITA T, KUROITA T, YASUMOTO M et al.: Synthesisand pharmacology of 3,4-dihydro-3-oxo-1,4-ben-zoxazine-8-carboxamide derivatives, a new class of po-tent serotonin-3 (5-HT3) receptor antagonists. Chem. Pharm. Bull. (1992) 40:624–630.
   PubMed Web of Science ®Google Scholar
• FUKUDA T, INABA KI, SHOJI H et al.: The antiemeticprofile of Y-25130, anew 5-HT3receptor antagonist Jpn. J. Pharrnacol. (1990) 52:339P.
   Google Scholar
• ASANO K, 00E M, IZUMI S et al.: Effect of Y-25130, aselective 5-HT3 receptor antagonist, on the colonic transit in rats. JPn. J. Pharmacol. (1992) 59:356P.
   Google Scholar
• MIYATA K, KAMATO T, YAMANO M et al.: Serotonin (5-HT3) receptor blocking activities of YM060, a novel 4,5,6,7-tetrahydrobenzitnidazole derivative, and its en-antiomer in anaesthetised rats. J. Pharmacol. Exp. Ther. (1991) 259:815–819.
   PubMed Web of Science ®Google Scholar
• ITO H, MIYATA K, KAMATO T et al.: Pharmacological properties of YM-060, a potent and selective serotonin 5-1rT3 receptor antagonist and its enantiomer in the isolated tissue. Gastroenterology (1991) 100:A453.
   Google Scholar
• WONG EHF, CLARK R, LEUNG E etal.: The interaction of RS-25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br.J. Pharrnacol. (1995) 114:851–859.
   Google Scholar
• EGLEN RM, LEE CH, SMITH WL et al.: Pharmacologicalcharacterisation of RS-25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol. (1995) 114:860–866.
   PubMed Web of Science ®Google Scholar
• FITZPATRICK LR, LAMBERT EM, PENDLEY CE et al.: RG 12915: a potent 5-HT3 antagonist that is an orally effec-tive inhibitor of cytotoxic drug-induced emesis in the ferret and dog. J. Pharmacol. Exp. Ther. (1990) 254:450–455.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ AG, PUIG J, BELETA J et al.: Pancopride, a potent and long- acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked ernes's. Furl. Pharmacol. (1992) 222:257–264.
   Web of Science ®Google Scholar
• DEWLAND P, CAMPOS AP, MARTINEZ-TOBED A: Single-dose pharmacokinetics and tolerance of pancopride in healthy volunteers. Pharrnacol. (1995) 45:177–178.
   Google Scholar
• SANCILIO LF, PINKUS LM, JACKSON CB et al.: Studies on the emetic and antiemetic properties of zacopride and its enantiomers. Eur. J. Pharmacol. (1991) 192:365-369. Emetic and antiemetic properties of zacopride.
   Google Scholar
• SANCILIO LF, PINKUS LM, JACKSON CB et al.: Emetic activity of zacopride in ferrets and its antagonism by 99. pharmacological agents. Eur. J. Pharmacol. (1990) 181:303–306.
   PubMed Web of Science ®Google Scholar
• DUMUIS A, SEBBEN M, BOCKAERT J: The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurones. Naunyn Schmiedebetg's Arch. Pharmacol. (1989) 340:403–410.
   PubMed Web of Science ®Google Scholar
• BHANDARI P, ANDREWS PLR: Preliminary evidence for the involvement of the putative 5-HT4 receptor in zaco-pride- and copper sulphate-induced vomiting in the ferret. Eur. J. Pharmacol. (1991) 204:273–280.
   PubMed Web of Science ®Google Scholar
• PISTERS KM, KRIS MG, TYSON LB et al.: Dose-ranging trial of zacopride: the emetic antietnetic? J. Natl. Cancer Inst. (1992) 84:717–718.
   Google Scholar
• GL'LLIKSON GW, LOEFFLER RF, VIRINA MA: Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J. Pharmacol. Exp. Ther. (1991) 258:103–110.
   PubMed Web of Science ®Google Scholar
• SOUKOP M, MCQUADE B, HUNTER E et al.: Ondansetron compared with metockpramide in the control of emesis and quality of life during repeated chemother- apy for breast cancer. Oncology (1992) 49:295–304.
   PubMedGoogle Scholar
• CUNNINGHAM D, GORE M, DAVIDSON N et al.: The real costs of ernes's. An economic analysis of ondansetron vs. metoclopranxide in controlling emesis in patients receiving chemotherapy for cancer. Eur.J. Cancer (1993) 29A:303-306. An economical analysis of ondansetron versus metoclopramide as antiemetics.
   Google Scholar
• BUXTON MJ, OBRIEN BJ: Economic evaluation of ondan-setron preliminary analysis using clinical trial data prior to price setting. Br, J. Cancer (1992) 66:564–567.
   Google Scholar
• JONES AL, LEE GJ, BOSANQUET N: The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur. J. Cancer (1993) 29A51–56.
   Google Scholar